• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

information for practice

news, new scholarship & more from around the world


advanced search
  • gary.holden@nyu.edu
  • @ Info4Practice
  • Archive
  • About
  • Help
  • Browse Key Journals
  • RSS Feeds

Choice of recall period for patient-reported outcome (PRO) measures: criteria for consideration

Abstract

Purpose  

Understand the choice of recall period for PRO measures based on intended use, characteristics of the disease, treatment,
and attributes of studies.

Methods  

Current practice and considerations were reviewed within several disease areas (overactive bladder, menopausal hot flashes,
niacin-induced flushing, osteoarthritis pain, irritable bowel symptoms, benign prostatic hyperplasia, and alopecia).

Results  

Rationales were identified for using different recall periods, including event-driven (immediate), daily, up to weekly, and
longer than weekly. This work demonstrates that (1) recall depends on what the PRO measure captures, its intended use, and
attributes of the disease and study; (2) within the same disease area, recall can vary depending on the concept or phenomenon
of interest; (3) recall must consider patient burden and their ability to easily and accurately recall the information requested;
and (4) recall must be consistent with the duration of the trial and the scheduled clinic visits.

Conclusions  

Shorter recall periods may underestimate symptom burden when symptoms have diurnal or day-to-day fluctuation and may place
undue burden on patients. On the other hand, recall intervals that are too long may either over- or underestimate the health
state. Therefore, appropriate criteria should be considered given attributes of the disease when selecting an adequate recall
period.

  • Content Type Journal Article
  • Pages 1-8
  • DOI 10.1007/s11136-011-0003-8
  • Authors
    • Josephine M. Norquist, Department of Epidemiology, Merck Research Laboratories, UG1D-60, P.O. Box 1000, North Wales, PA 19454, USA
    • Cynthia Girman, Department of Epidemiology, Merck Research Laboratories, UG1D-60, P.O. Box 1000, North Wales, PA 19454, USA
    • Sheri Fehnel, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA
    • Carla DeMuro-Mercon, RTI Health Solutions, RTI International, Research Triangle Park, NC, USA
    • Nancy Santanello, Department of Epidemiology, Merck Research Laboratories, UG1D-60, P.O. Box 1000, North Wales, PA 19454, USA
    • Journal Quality of Life Research
    • Online ISSN 1573-2649
    • Print ISSN 0962-9343
Posted in: Journal Article Abstracts on 09/12/2011 | Link to this post on IFP |
Share

Primary Sidebar

Categories

Category RSS Feeds

  • Calls & Consultations
  • Clinical Trials
  • Funding
  • Grey Literature
  • Guidelines Plus
  • History
  • Infographics
  • Journal Article Abstracts
  • Meta-analyses - Systematic Reviews
  • Monographs & Edited Collections
  • News
  • Open Access Journal Articles
  • Podcasts
  • Video

© 1993-2025 Dr. Gary Holden. All rights reserved.

gary.holden@nyu.edu
@Info4Practice